Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive

Pantoja, Márcia; Medeiros, Tatiane; Baccarin, Maria Carolina; Morais, Sirlei Siani; Bahamondes, Luís; Fernandes, Arlete

doi:10.1016/j.contraception.2009.07.008

Cited by 56 publications

(50 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five of the 16 studies showed or reported significant differences between groups in weight change or body composition change (Salem 1984;Sule 2005;Pantoja 2010;Dal'Ava 2012). Two of the five studies examined DMPA, two focused on Norplant (six capsules) and one examined the LNG-IUS.…”

Section: Summary Of Main Resultsmentioning

confidence: 99%

“…• Three retrospective studies compared a POC to a non-hormonal IUD (Taneepanichskul 1998;Sule 2005;Pantoja 2010). Only Pantoja 2010 showed more weight gain for the DMPA group at one, two, and three years, but interestingly not within the obese group (BMI >=30).…”

Section: Summary Of Main Resultsmentioning

confidence: 99%

“…Two studies considered confounding in the design (Pantoja 2010;Dal'Ava 2012). Both matched on age and baseline BMI.…”

Section: Selective Reporting (Reporting Bias)-after Randomization Tamentioning

confidence: 99%

See 2 more Smart Citations

Progestin-only contraceptives: effects on weight

Lopez¹,

Edelman

Chen-Mok³

et al. 2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Section: Summary Of Main Resultsmentioning

confidence: 99%

Section: Summary Of Main Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Progestin-only contraceptives: effects on weight

Lopez¹,

Edelman

Chen-Mok³

et al. 2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

“…Our study found that after 12 months of follow-up the injectable DMPA users had significant weight gain (3.01 kg). As most prospective studies evaluating the effect of DMPA were for at least 30 months (6,8,9), we can consider that the follow-up period of our study is short compared to the others, but we can already observe significant changes in important variables studied.…”

Section: Discussionmentioning

confidence: 94%

“…According to the characteristics of contraceptive efficacy, safety and low cost, and ease of access due to its ready availability from public health systems in several countries, including Brazil, millions of women choose to use this method (6). Despite having a potential negative effect on bones, the most common reason for discontinuing use of DMPA is increased body weight (7).…”

Section: Introductionmentioning

confidence: 99%

Body composition, resting energy expenditure and inflammatory markers: impact in users of depot medroxyprogesterone acetate after 12 months follow-up

Batista

Souza

Marin

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate for 12 months the changes of body weight using Depot Medroxyprogesterone Acetate (DMPA) and if these changes are related to inflammatory markers. Subjects and methods: Twenty women of childbearing age who chose the DMPA, without previous use of this method, BMI < 30 kg/m², and 17 women using IUD TCu 380A, participated in the study. At the baseline and after one year, changes in weight gain, body composition by the bioimpedance electric method, resting energy expenditure (REE) by the indirect calorimetry method, inflammatory markers and HOMA-IR were assessed. Results: After 12 months of evaluation, we could observe a significant increase in the DMPA group in weight (3,01 kg) and BMI, while the IUD group's only significant increase was observed in the BMI. Relative to REE there was an increase of basal metabolic rate (BMR) in both groups after one year. The sub-group DMPA that gained < 3 kg had increased significant weight, BMI and body surface (BS) with respiratory quotient (RQ) reduction, while the sub-group that gained ≥ 3 kg had a significant increase in weight, BMI, BS, fat-free mass, fat mass, BMR, Leptin, HOMA-IR and waist circumference, with RQ significantly reduced. Conclusion: Our study found significant changes in weight, body composition and metabolic profile of the population studied in the first 12 months of contraceptive use. These changes mainly increased body weight, leptin levels and HOMA-IR which can contribute to the development of some chronic complications, including obesity, insulin resistance and diabetes mellitus. Arch Endocrinol Metab. 2017;61(1):70-5

show abstract